IceCure Medical Ltd (ICCM)
NASDAQ: ICCM · Real-Time Price · USD
0.603
-0.007 (-1.20%)
At close: Nov 20, 2024, 4:00 PM
0.591
-0.011 (-1.86%)
Pre-market: Nov 21, 2024, 7:15 AM EST
IceCure Medical Employees
As of December 31, 2023, IceCure Medical had 77 total employees, including 71 full-time and 6 part-time employees. The number of employees increased by 5 or 6.94% compared to the previous year.
Employees
77
Change (1Y)
5
Growth (1Y)
6.94%
Revenue / Employee
$43,325
Profits / Employee
-$177,727
Market Cap
29.83M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 77 | 5 | 6.94% |
Dec 31, 2022 | 72 | 8 | 12.50% |
Dec 31, 2021 | 64 | 17 | 36.17% |
Dec 31, 2020 | 47 | - | - |
Related Stocks
Company Name | Employees |
---|---|
IRIDEX | 111 |
DURECT | 58 |
Passage Bio | 58 |
SAB Biotherapeutics | 57 |
Curis | 49 |
KALA BIO | 43 |
AN2 Therapeutics | 41 |
NeurAxis | 19 |
ICCM News
- 1 day ago - IceCure Medical to Report Third Quarter 2024 Financial & Operational Results on November 26, 2024 - PRNewsWire
- 2 days ago - IceCure's ProSense® Chosen for Breast Cryoablation Study Led by the Prestigious European Institute of Oncology with Sponsorship from the Italian Ministry of Health - PRNewsWire
- 13 days ago - FDA Advisory Panel Votes in Favor of IceCure's ProSense® Cryoablation Benefit-Risk Profile in Early-Stage Low Risk Breast Cancer - PRNewsWire
- 23 days ago - Upcoming FDA Advisory Panel for IceCure's ProSense® Marketing Authorization Receives Large Number of Public Comments from Stakeholders - PRNewsWire
- 4 weeks ago - IceCure Receives Notice of Allowance from U.S. Patent and Trademark Office for its Next-Generation Cryoablation System - PRNewsWire
- 6 weeks ago - IceCure's ProSense® Featured in 6 Global Studies on Cryoablation of Breast Tumors at the 2024 European Society of Breast Imaging Conference - PRNewsWire
- 2 months ago - IceCure's ICE3 5-Year Trial Results Published in the Peer Reviewed Annals of Surgical Oncology Journal: ProSense® Cryoablation Without Excision for Early-Stage, Low-Risk Breast Cancer Demonstrates 96.3% Recurrence Free Rate - PRNewsWire
- 2 months ago - Study Published in the British Journal of Radiology Demonstrates IceCure's ProSense® is a Safe Procedure with 97.7% Technical Success Rate in Treating Tumors of the Lung, Bone, and Soft Tissues - PRNewsWire